Tilting at windmills

The total windmill capacity in India is now 9,000MW (3,594 MW in 2005) and around Rs30,000 crore has been invested in various windmill projects across the country.

Every reputed industrial group—even those who have nothing to do with the power sector— wants a piece of the windmill pie. According to the Centre for Wind Energy Technology (C-WET), India has a wind farm potential of 48,000 MW. This will require an investment of Rs3,00,000 crore.

But here’s the catch. The investment is nothing other than a depreciation machine with hardly any productivity. If the total potential of 48,000MW is realised, this will generate 48-75 billion KWh of electricity whereas if this amount is spent on thermal plants worth 75,000 MW, they will generate 525 billion KWh of electricity.
 
For instance, Tata Power put up its 80 MW wind power project in a windy area in 2008-09; it produced 1.6 million KWh for each MW of the windmill project. At its Trombay power house—where Tata Power has its 1,580MW thermal power project—it produced 9,845 million units accounting for 6.2 million KWh per MW. However, Tata’s windmill project was set up in a windy area. The situation is worse in other places where wind blades hardly move and generate negligible power.
 
A comparison of thermal power plants and windmill projects throws up some surprising figures. Thermal plants generate around 6-7 million KWh per MW of capacity despite their low efficiency of 36% as power is generated from coal to steam to turbine generator. Against this, windmills have no loss of efficiency in the process of converting wind to electricity as wind blades are directly attached with the rotor and generator. Despite this they get only one million KWh of electricity per MW.
 
Only plus point with windmills is that they have no raw material cost. But looking at the huge cost which is 1.5 times higher than thermal plant, why is the government promoting wind mills?
 
One answer may be thanks to depreciation benefits. The entire cost of a windmill plant can be depreciated in the first year of operation if it is used for more than 180 days other wise 80% cost can be depreciated even if it is used for one day under section 32 of the Income-Tax Act. 

User

COMMENTS

siddharth

7 years ago

which will be the perfect place for a windmill projejct in india?
and howmuch numbers of windmills should be planted by them??
considering self as a former or the chairman of the joint stock company...........

Foreign tourist spends go up in India
This is a great time for the hospitality industry. The foreign tourist is spending more in India as compared to the previous year. According to government data, in September, foreign tourist arrivals dipped by 4.1 % to 3.17 lakh but average spending has increased by 28.8% to Rs1,19,810. The total foreign exchange revenue earned was Rs3,798 crore. The dollar exchange rate has contributed around 5% to this growth and the remaining 24% growth has come from increased expenses in longer term stay in hotels and travelling spends. The government has declared the current year as “Visit India Year”.
Dhruv Rathi [email protected]
 
 
 
 

User

First past the post
Suven Life Science’s focussed approach on drug discovery in the central nervous system (CNS) is helping it make more headway than any other research company in the drug industry. Suven has recently secured a product patent for its new molecule SUVN-502 from India, Mexico, South Africa, Singapore, New Zealand, South Korea, Australia and Europe. SUVN-502 has completed phase I studies and is entering into phase II stage of clinical research. This molecule is a clinical candidate for Alzheimer’s disease and schizophrenia and can corner a major market share in the $110-billion CNS therapy arena. Global CNS therapies include anti-psychotic, anti-depressant, anti-epileptic and auto-immune drugs accounting for $22.8 billion ($14.69 billion in 2004), $ 20.3 billion ($20.64 billion in 2004), $16.9 billion ($11.57 billion in 2004) and $15.9 billion ($ 6.7 billion in 2004) market size respectively in 2008.
 
The company spends around 25% of sales on drug discovery which is one of the highest among drug companies. Industy’s average R&D expenditure is around 4% of total sales. The company spent Rs 35 crore on drug research in 2008-09 including Rs 29 crore in recurring expenditure. The company is doing research in six CNS categories targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and obesity.
- Dhruv Rathi [email protected]
 
 
 
 
 

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)